Cullinan Therapeutics (CGEM) investor relations material

Executive summary

• Focused on developing T cell engagers for autoimmune diseases and cancer, with a clinical-stage pipeline and multiple ongoing trials in immunology and oncology.

• Presented promising initial clinical data for CLN-978 and velinotamig in SLE and RA, showing potential for immune reset and disease activity improvement.

• No products approved or revenue from product sales; operations funded primarily through equity and licensing.

• Significant operating losses and negative cash flows from operations since inception; accumulated deficit of $691.5 million as of June 30, 2026.

• Positive FDA feedback enables initiation of a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML in Q3 2026.

Financial highlights

• Cash, cash equivalents, investments, and interest receivable totaled $356 million as of June 30, 2026, providing runway into 2029.

• Net loss was $53.7 million for Q2 2026 and $103.4 million for the first half of 2026, compared to $70.1 million and $118.6 million for the same periods in 2025.

• Research and development expenses decreased to $44.4 million in Q2 2026 from $61.0 million in Q2 2025, mainly due to a one-time $20 million licensing fee in 2025.

• General and administrative expenses decreased to $12.8 million in Q2 2026 from $14.8 million in Q2 2025.

• Interest income was $3.6 million in Q2 2026, down from $5.9 million in Q2 2025.

Outlook and guidance

• Current cash and investments expected to fund operations for at least twelve months from the financial statement issuance date, with runway projected into 2029 under current operating plan.

• Multi-dose regimen data for CLN-978 in RA expected in Q3 2026 and in SLE in Q4 2026; Phase 2 expansions to begin early 2027.

• Velinotamig multi-dose data in SLE expected Q4 2026; global Phase 1/2 basket study in autoimmune cytopenias to start early 2027.

• NDA for zipalertinib accepted by FDA, with PDUFA date set for February 27, 2027.

• Anticipates continued operating losses and negative cash flows; future funding may be required for expanded R&D and commercialization.